| Popis: |
Background: The coronavirus disease 2019 (COVID-19) that is caused by the severe acute respiratory syndrome-coronavirus2 (SARS-CoV2) has spread rapidly worldwide during the past nearly a year. SARS-CoV-2 particles spread through the respiratory mucosa and infect other cells, causing a storm of cytokines in the body1, producing a series of immune responses, and causing multiple organ dysfunction, including the heart. Some patients present with cardiovascular system damage, such as palpitations and shortness of breath as the first or secondary symptoms. Previous studies suggested that LDH, α-HBDH, CK and CK-MB reflect myocardial function.2 Here, we aim to investigate whether these markers can predict poor prognosis of patients with COVID-19. Methods: We collected data from 2338 patients with laboratory-confirmed COVID-19. Patients were then screened, and we focused on 49 moderate cases, 98 severe cases and 53 critical cases (27 recovered cases, 26 deaths). We divided these patients into non-critical group (n = 49) and critical group (n = 151). Then, we also divided the length of hospitalization into five time points, namely admission, 25%, 50%, 75% and discharge or death, according to the principle of interquartile distance. Blood was collected from patients on the above five time points. Patients with five blood tests were 49 moderate cases, 98 severe cases and 53 critical cases (27 recovered cases, 26 deaths). LDH, α-HBDH, CK and CK-MB of each group were collected for analysis.Results: Our research found that α-HBDH and LDH of the critical groups significantly increased, diagnostic efficiency of LDH and α-HBDH have more advantages than that of CK and CK-MB compared with the non-critical group, and patients with α-HBDH greater than 182IU/L and LDH greater than 250IU/L at admission had lower survival rates. Then, CK, LDH, α-HBDH and CK-MB were observed dynamically in the 49 moderate cases, 98 severe cases and 53 critical cases (27 recovered cases, 26 deaths). It turns out that they increased progressively in the dead patients, while they decreased regularly in the severe case and the critical cases(recovered)(P＜0.001).Conclusions: The prognosis of patients with abnormal α-HBDH was poor on admission. α-HBDH is a probably higher sensitive and specific the biomarkers of poor prognosis in patients with COVID-19. This predictor may help clinicians identify patients with a poor prognosis and may be useful for guiding clinical decision-making at an early stage. |
